Cytovation
WebCytovation General Information. Description. Developer of synthetic peptides designed to provide treatment of benign skin tumors and different types of cancer. The company develops CyPep-1 peptide with a novel mechanism of action that guides the immune system to recognize and eradicate tumors, enabling patients to get treatment for cutaneous … WebFeb 15, 2024 · Bergen, Norway, 15 February 2024 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class targeted tumor membrane immunotherapy,...
Cytovation
Did you know?
WebJan 27, 2024 · Cytovation AS, a clinical-stage oncology company based in Norway, raised $20 million in a Series A financing round. Funds will be used to advance the development of its immunotherapy candidate CyPep-1 in combination … WebMar 21, 2024 · About Cytovation Cytovation ASA is a privately held, clinical stage immune-oncology company focused on the development of CyPep-1, a first-in-class immunotherapy targeting the cell membrane of ...
WebMay 27, 2024 · BERGEN, Norway and SCHIPHOL, Netherlands, May 27, 2024 /PRNewswire/ -- Cytovation AS ("Cytovation"), a clinical-stage biotechnology company focused on developing CyPep-1, a next-generation...
WebFeb 23, 2024 · Cytovation overview. Cytovation is a biotech company that develops novel therapeutic agents for skin diseases and infections. The company’s lead candidate includes CyPep-1, a novel peptide and an anti-bacterial compound. Its CyPep-1 is developed for skin disorders such as papilloma diseases, tumors of skin warts caused from HPV transfected ... WebFeb 8, 2024 · Cytovation AS is a privately held, clinical stage immune-oncology company focused on the development of CyPep-1, a first-in-class agent targeting the cell membrane of tumor cells.
WebCyViation provides holistic cybersecurity solutions for commercial airlines and private jets to increase aircraft cyber resilience.
WebMar 31, 2024 · 40P - Updated data from the Phase I Beamion Lung 1 trial of BI 1810631, a HER2 TKI, in patients (pts) with advanced solid tumours with HER2 aberrations graphic organizers for psychologyWebFeb 17, 2024 · Bergen, Norway, 15 February 2024 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class targeted tumor membrane immunotherapy, announces that the first patient has been dosed in its Phase 2a study investigating CyPep-1 monotherapy in patients with advanced … graphic organizers for science classesWebCytovation appoints Iman Barilero as Chief Development Officer Bergen, Norway, 21 March 2024 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy CyPep-1, announces that Dr. Iman Barilero has joined the company as Chief Development Officer. chiropody thatchamWebJan 26, 2024 · Now, Cytovation, a Bergen-based Norwegian immuno-oncology startup, has announced a Series A fundraising round of €17.7M (NOK 180M). This is the largest biotech Series A round the country has seen since 2005, when Algeta raised €23.5M to develop a radiopharmaceutical treatment for bone metastasis of prostate cancer. chiropody telfordWebCytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway. Lists Featuring This Company. Edit Lists Featuring This Company Section. Medical … graphic organizers in artWebMar 18, 2024 · BERGEN, NORWAY, 18 March 2024 – Cytovation AS, a privately held biotech company, announces that the first patients have been treated in a Phase I clinical study with CyPep-1, a novel therapeutic agent being developed as a new topical therapy for HPV-induced warts. graphic organizer showing relationshipsWebOct 27, 2024 · BERGEN, Norway, Oct. 27, 2024 /PRNewswire/ -- Cytovation AS, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy,... graphic organizers for writing high school